

(FILE 'HOME' ENTERED AT 17:12:53 ON 09 DEC 2002)

FILE 'CAPLUS' ENTERED AT 17:13:10 ON 09 DEC 2002

FILE 'REGISTRY' ENTERED AT 17:13:15 ON 09 DEC 2002

L1 STRUCTURE UPLOADED
L2 1 S L1 SSS SAM
L3 2 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 17:14:18 ON 09 DEC 2002

L4 5 S L3
L5 4 S L4 AND HEPATITIS


Uploading 09837491.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Me, OH, MeO, C(O)CH₃, NH₂, NO₂, Cl, Br, F, I, NH, N

G2 G1, H

Structure attributes must be viewed using STN Express query preparation.

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:444490 CAPLUS

DOCUMENT NUMBER: 137:15760

TITLE: Ribavirin derivative-interferon-.alpha. combination therapy for eradicating detectable HCV-RNA in patients having chronic **hepatitis** C infection, and preparation of ribavirin derivatives

INVENTOR(S): Ganguly, Ashit K.; McCormick, Jinping; Lovey, Raymond G.; Bennett, Frank; Saksena, Anil K.; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S., 41 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6403564	B1	20020611	US 1999-417884	19991014
PRIORITY APPLN. INFO.:			US 1998-104566P	P 19981016
			US 1999-142854P	P 19990707

OTHER SOURCE(S): MARPAT 137:15760

AB A method for treating a patient having chronic **hepatitis** C infection to eradicate detectable HCV-RNA involves a combination therapy using a therapeutically effective amt. of ribavirin deriv. and a therapeutically effective amt. of interferon-.alpha. for a time period of from 20 up to 80 wk. Ribavirin derivs. of the invention metabolize in vivo into ribavirin.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:798236 CAPLUS

DOCUMENT NUMBER: 135:339213

TITLE: Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic **hepatitis** C infection

INVENTOR(S): Ganguly, Ashit K.; McCormick, Jinping; Lovey, Raymond G.; Bennett, Frank; Saksena, Anil K.; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081359	A1	20011101	WO 2001-US12760	20010418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002055473	A1	20020509	US 2001-837491	20010418
PRIORITY APPLN. INFO.:			US 2000-198801P	P 20000420

AB Ribavirin derivs. were prepd. and combined therapy with interferon-.alpha. is described for the treatment of susceptible viral infections, for example, chronic **hepatitis** C infections.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:277992 CAPLUS

DOCUMENT NUMBER: 132:293978

TITLE: Preparation of Ribavirin derivs. and use in interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic **hepatitis** C infection

INVENTOR(S): Ganguly, Ashit K.; McCormick, Jinping; Lovey, Raymond G.; Bennett, Frank; Saksena, Anil K.; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corp., USA

SOURCE: PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023455	A1	20000427	WO 1999-US21450	19991014
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1121370	A1	20010808	EP 1999-970663	19991014
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1998-174059 A2 19981016
WO 1999-US21450 W 19991014

OTHER SOURCE(S): MARPAT 132:293978

GI



AB Ribavirin derivs. I [R₁, R₂ = straight or branched chain polyalkylene oxide polymer conjugate, H, R₃-(W)_x-Z, (HO)₂PO, SO₃H; W = O, S, NH or imino; x = 0, 1; Z = CO, C(S), C(NH), PO(OH); R₃ = H, (un)substituted alkyl, alkanoyl, aryl, alkenyl, alkynyl or heterocyclic, cycloalkyl, amino, hydroxy, alkoxy derivs.], and pharmaceutical compns. contg. them

as well as their use to treat patients having susceptible viral infections, alone and in combination with a therapeutically effective amt. of interferon-alpha are disclosed. Thus, I (R1 = H; R2 = pivaloyl) was prepd. for treating susceptible viral infections, esp. **hepatitis C** viral infections.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:277991 CAPLUS

DOCUMENT NUMBER: 132:293977

TITLE: Preparation of Ribavirin derivs. and use in interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic **hepatitis C** infection

INVENTOR(S): Ganguly, Ashit K.; McCormick, Jinping; Lovey, Raymond G.; Bennett, Frank; Saksena, Anil K.; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023454	A1	20000427	WO 1999-US21448	19991014
W:				
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6277830	B1	20010821	US 1999-348534	19990707
CA 2346447	AA	20000427	CA 1999-2346447	19991014
EP 1121369	A1	20010808	EP 1999-970662	19991014
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9915546	A	20010814	BR 1999-15546	19991014
JP 2002527522	T2	20020827	JP 2000-577180	19991014
NO 2001001789	A	20010611	NO 2001-1789	20010409
PRIORITY APPLN. INFO.:			US 1998-174059	A 19981016
			US 1999-348534	A 19990707
			WO 1999-US21448	W 19991014
OTHER SOURCE(S):		MARPAT 132:293977		
GI				



AB A method for treating a patient having chronic **hepatitis C** infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amt. of ribavirin deriv. of I [R1, R2 = H, R3-(W)x-Z ; SO₃H; W = O, S, NH or imino; x= 0, 1; Z = CO, C(S)-(HO)₂PO, PO(OH); R3 = H, (un)substituted alkyl, alkanoyl, aryl, alkenyl, alkynyl or heterocyclic, cycloalkyl, amino, carboxyalkyl, hydroxyalkyl, aminoalkyl derivs.] and a therapeutically effective amt. of interferon-alpha for a time period of from 20 up to 80 wk. Thus, I (R1 = H; R2 = pivaloyl) was prepd. and Ribavirin Conc. of pooled Rat Plasma (2 rats/pool) following oral administration of 40 mpk in 20% hydroxypropyl-.beta.-cyclodextrin was AUC = 1523.65 (ng.hr/mL) and %CV = 23.56.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT